De Novo Mutation in Non-Tyrosine Kinase Domain of ROS1 as a Potential Predictor of Immune Checkpoint Inhibitors in Melanoma

PURPOSE: Despite the success of targeted therapy in c-ros oncogene 1 (ROS1)-rearranged cancers, especially non-small cell lung cancer (NSCLC), the clinical significance of ROS1 de novo mutation has not yet been understood. We sought to elucidate the predictive effect of ROS1 mutation for immune chec...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Si-Cong, Zhu, Hong-Bo, Wang, Jian, Zhang, Yan-Pei, Guo, Xue-Jun, Long, Li-Li, Guo, Ze-Qin, Wu, De-Hua, Dong, Zhong-Yi, Bai, Xue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8247586/
https://www.ncbi.nlm.nih.gov/pubmed/34221982
http://dx.doi.org/10.3389/fonc.2021.666145

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8247586/
https://www.ncbi.nlm.nih.gov/pubmed/34221982
http://dx.doi.org/10.3389/fonc.2021.666145

Ejemplares similares